Arrowhead Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARWR Nasdaq 2836 arrowheadpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals (ARWR) Reports Fresh ARO MAPT Data, Is The Stock Still Cheap? - Oct 16th, 2026 3:09 am
ARWR: Interim ARO-MAPT Data Shows Potential for TRiM™ Platform in CNS Diseases - Oct 15th, 2026 9:08 am
Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study - Oct 14th, 2026 5:02 pm
Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial - Oct 14th, 2026 11:21 am
Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut? - Oct 14th, 2026 10:43 am
Arrowhead’s Alzheimer’s Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial – Here’s What Investors Need To Know - Oct 14th, 2026 9:36 am
Arrowhead jumps as breakthrough Alzheimer’s drug clears brain barrier - Oct 14th, 2026 6:37 am
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers - Oct 14th, 2026 5:30 am
Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist - Oct 11th, 2026 8:17 pm
3 Biotech Stocks To Watch In October 2026 - Oct 9th, 2026 6:16 pm
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia - Oct 7th, 2026 5:30 am
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies - Sep 29th, 2026 5:30 am
RNAi drug specialist ADARx raises $446M IPO - Sep 24th, 2026 6:36 pm
ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near - Sep 24th, 2026 5:20 am
Arrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still Holds - Sep 18th, 2026 10:18 pm
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress - Sep 18th, 2026 6:02 pm
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands - Sep 18th, 2026 3:02 pm
RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics - Sep 18th, 2026 4:42 am
Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’ - Sep 16th, 2026 11:41 am
Arrowhead Achieves Clinical Validation for New Drug Platform - Sep 16th, 2026 5:39 am